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Excess reactive oxygen species production by mitochondria is a key mechanism of age-related 32 
vascular dysfunction. Our laboratory has shown that supplementation with the mitochondrial-33 
targeted antioxidant MitoQ improves vascular endothelial function by reducing mitochondrial 34 
reactive oxygen species and ameliorates arterial stiffening in old mice, but the effects in humans 35 
are unknown. Here we sought to translate our preclinical findings to humans and determine the 36 
safety and efficacy of MitoQ. Twenty healthy older adults (60-79 years) with impaired 37 
endothelial function (brachial artery flow-mediated dilation <6%) underwent six weeks of oral 38 
supplementation with MitoQ (20 mg/day) or placebo in a randomized, placebo-controlled, 39 
double-blind, crossover design study. MitoQ was well tolerated and plasma MitoQ was higher 40 
after the treatment vs. placebo period (P<0.05). Brachial artery flow-mediated dilation was 42% 41 
higher after MitoQ vs. placebo (P<0.05); the improvement was associated with amelioration of 42 
mitochondrial reactive oxygen species-related suppression of endothelial function (assessed as 43 
the increase in flow-mediated dilation with acute, supra-therapeutic MitoQ [160 mg] 44 
administration, n=9, P<0.05). Aortic stiffness (carotid-femoral pulse wave velocity) was lower 45 
after MitoQ vs. placebo (P<0.05) in participants with elevated baseline levels (carotid-femoral 46 
pulse wave velocity >7.60 m/s, n=11). Plasma oxidized low-density lipoprotein, a marker of 47 
oxidative stress, also was lower after MitoQ vs. placebo (P<0.05). Participant characteristics, 48 
endothelium-independent dilation (sublingual nitroglycerin) and circulating markers of 49 
inflammation were not different (all P>0.1). These findings in humans extend earlier preclinical 50 
observations and suggest that MitoQ and other therapeutic strategies targeting mitochondrial 51 
reactive oxygen species may hold promise for treating age-related vascular dysfunction. 52 
 53 





 Cardiovascular diseases (CVD) remain the leading cause of morbidity and mortality in 58 
developed societies.1, 2 Advancing age is the primary risk factor for CVD, which is largely 59 
mediated by adverse changes to arteries.1, 3 Two features of vascular aging that are key 60 
antecedents to CVD are the development of endothelial dysfunction, as assessed by reduced 61 
endothelium-dependent dilation (EDD), and stiffening of the large elastic arteries (i.e., aortic 62 
stiffening).3, 4 Vascular dysfunction with age is a consequence of excessive superoxide-related 63 
oxidative stress, much of which is of mitochondrial origin.5-7 Given the projected increase in 64 
CVD prevalence in the coming decades, driven mainly by increases in the number of middle-65 
aged and older (MA/O) adults,8, 9 identifying novel strategies that reduce excess mitochondrial 66 
reactive oxygen species (mtROS) to improve vascular function and reduce CVD risk in this 67 
population is a biomedical priority. 68 
MitoQ is a mitochondria-targeted antioxidant consisting of the naturally occurring 69 
antioxidant ubiquinol attached to a lipophilic cation; the lipophilicity and positive charge of this 70 
compound enable it to cross cell membranes and accumulate on the matrix facing the surface of 71 
the mitochondrial inner membrane where it is optimally positioned to reduce mtROS.10, 11 72 
Preclinical findings from our laboratory show that 4 weeks of oral supplementation of MitoQ 73 
(drinking water) completely restores EDD in old mice to levels observed in young mice.6 The 74 
improvement in EDD in old mice was mediated by a suppression of mtROS, as indicated by an 75 
increase in EDD with acute MitoQ administration in untreated, but not in MitoQ-treated, 76 
animals.6 More recently, we reported that 4 weeks of MitoQ treatment also ameliorated age-77 
related increases in aortic stiffness in old mice, as indicated by a reduction in aortic pulse wave 78 
velocity (PWV).12 MitoQ supplementation did not impact endothelial function or aortic stiffness in 79 
young mice.6, 12  80 
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MitoQ has been used safely in Phase II clinical trials for Parkinson’s and liver disease.13, 81 
14 Moreover, MitoQ is now available as a dietary supplement and recently was administered 82 
chronically (3 weeks) to healthy young adults without adverse effects.15 However, presently the 83 
efficacy of chronic MitoQ supplementation for improving vascular function in healthy MA/O 84 
adults is unknown. Accordingly, we sought to translate our preclinical findings to humans by 85 
conducting the first randomized, double-blind, placebo-controlled clinical trial with MitoQ in 86 
healthy late MA/O humans (crossover design with 6-week intervention arms). EDD, as 87 
measured by nitric oxide (NO)-dependent brachial artery flow-mediated dilation (BAFMD), was 88 
our primary outcome. To gain mechanistic insight into the possible role of reduced tonic 89 
suppression of EDD by mtROS in mediating improvements in endothelial function with MitoQ 90 
supplementation, we used a novel functional bioassay in which the acute change in BAFMD in 91 
response to a single supra-therapeutic dose of oral MitoQ was compared after both the active 92 
treatment and placebo phases of the trial. Based on our recent preclinical findings in mice,12 we 93 
also took the opportunity to evaluate the impact of MitoQ on aortic stiffness, assessed 94 
translationally using carotid-femoral PWV (CFPWV). Given that this trial was the first conducted 95 
in healthy MA/O adults, safety, tolerability and plasma levels of MitoQ with treatment also were 96 
evaluated. Lastly, we assessed changes in circulating markers of oxidative stress and 97 
inflammation for additional mechanistic insight. 98 
 99 
Materials and Methods 100 
All procedures were reviewed and approved by the Institutional Review Board at the 101 
University of Colorado Boulder. The nature, benefits, and risks of all study procedures were 102 
explained to volunteers and their written informed consent was obtained before participation in 103 
the study. This trial was registered on ClinicalTrials.gov (NCT02597023). All measurements 104 
were performed at the University of Colorado Boulder Clinical Translational Research Center 105 
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(CTRC). The Food and Drug Administration categorized MitoQ as a dietary supplement for the 106 
manner utilized in this study and, as such, deemed that an IND was not needed. The data 107 
supporting the findings of this study are available from the corresponding author upon 108 
reasonable request.  109 
Participants. Late MA/O men and postmenopausal women aged 60 to 79 years from 110 
Boulder County, Colorado and the surrounding areas were studied. All participants were non-111 
smokers and free of clinical diseases, including peripheral arterial disease (ankle-brachial index 112 
>0.90) and overt CVD as determined by medical history, physical examination, blood 113 
chemistries, and blood pressure and electrocardiogram at rest and during incremental treadmill 114 
exercise. All participants demonstrated age-associated impairments in endothelial function at 115 
screening, defined as BAFMD <6%. Potential participants were excluded if they had abnormal 116 
blood chemistries, alcohol dependence, uncontrolled thyroid disease, severe obesity (body 117 
mass index [BMI] >40 kg/m2), or were not weight stable (defined as >2.5 kg change in body 118 
mass) for at least 3 months prior to enrolling in the study.  119 
Study design, randomization, and intervention. The study design consisted of a 2 x 120 
6-week randomized, double-blind, placebo-controlled, crossover clinical trial. To optimize the 121 
potential for observing effects of treatment, participants consumed MitoQ at the upper limit of 122 
the manufacturer recommended dose (20 mg, 1x/day; MitoQ Limited) or identical placebo 123 
capsules for 6 weeks before crossing over to the other treatment arm in a randomly determined 124 
order. Randomization was performed by a member of the study team not involved in the 125 
assessment of outcomes, and a block randomization scheme stratified for age and sex was 126 
used. MitoQ or placebo capsules were taken once each morning with breakfast. Every 2 weeks 127 
during the active treatment and placebo phases, in-person check-in visits were performed to 128 
exchange intervention capsules (a precise number of capsules were allocated until the 129 
participant’s next visit) and to assess participant adherence by survey and pill count. Tolerability 130 
and side effects were also evaluated during these check-in visits; treatment-emergent adverse 131 
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events were documented throughout the study by the CTRC staff and reported to the CTRC 132 
Safety Monitoring Committee and the Institutional Review Board. 133 
Measurements. All measurements were performed following a 12-hour fast from food 134 
(water allowed) and caffeine, a 24-hour abstention from alcohol, physical activity, prescription 135 
medications and the study compound (MitoQ and placebo) and a 48-hour abstention from over 136 
the counter medications and supplements.16 A single study investigator who was blinded to 137 
treatment condition of the subject performed all vascular data acquisition and analysis. 138 
Participant characteristics and clinical blood assays. BMI was determined by 139 
anthropometry17 and arterial systolic and diastolic blood pressures were assessed in triplicate 140 
over the brachial artery at rest with a semi-automated device (Dinamap XL, Johnson & 141 
Johnson) at the end of each intervention phase and at check-in visits. Leisure time physical 142 
activity was determined by the Modifiable Activity Questionnaire at the end of each intervention 143 
phase.18 144 
Blood samples were drawn from an intravenous catheter the cubital vein at screening 145 
and after each treatment arm. The Colorado Clinical and Translational Sciences Institute CTRC 146 
Core Laboratory and Boulder Community Hospital Clinical Laboratory performed the following 147 
blood assays as previously described.19 Fasting serum lipids were determined with standard 148 
assays. Fasting plasma glucose was measured by reflective spectrophotometry (Ortho Clinical 149 
Diagnostics). Plasma oxidized low-density lipoprotein (LDL) and serum interleukin (IL)-6 were 150 
assessed by ELISA (Mercodia). Serum high-sensitivity C-reactive protein was measured by 151 
immunoturbidimetry (Beckman Coulter).  152 
Plasma MitoQ levels. EDTA-treated plasma collected 24-26 hours after capsule 153 
ingestion following each 6-week intervention period was obtained to determine the effects of 154 
chronic MitoQ supplementation on circulating MitoQ levels in plasma. Plasma samples were 155 
analyzed by reversed-phase liquid chromatography using gradient elution with acetonitile, 156 
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water, and formic acid and the deuterated compound (d15-MitoQ) was used as an internal 157 
standard, as previously described.20  158 
Vascular endothelial function. EDD was determined by NO-dependent BAFMD (using 159 
a five-minute forearm cuff occlusion) using high-resolution ultrasonography (Toshiba Xario XG), 160 
as described previously.16, 21 BAFMD was measured at screening to establish baseline 161 
endothelial dysfunction and after each 6-week supplementation period. BAFMD is reported as 162 
percentage and absolute change from baseline diameter.16 BAFMD shear rate was calculated 163 
as: [8 × mean velocity (m/s)]/occlusion diameter (m).16 Brachial artery dilation following 0.4 mg 164 
sublingual nitroglycerin was measured after each 6-week supplementation period to control for 165 
changes in smooth muscle sensitivity to NO. Dilation with nitroglycerin is reported as percent 166 
change from baseline diameter. Brachial artery diameters and blood velocities were captured 167 
and analyzed by Vascular Research Tools 5.10.9 (Medical Imaging Applications). 168 
MtROS-mediated suppression of vascular endothelial function. After each 6-week 169 
treatment arm, BAFMD was measured before and 1 hour after an acute 160 mg oral dose of 170 
MitoQ, used to temporarily and reversibly reduce mtROS. The difference in FMD after vs. before 171 
acute oral MitoQ was taken as a measure of tonic suppression of EDD by mtROS.  172 
Aortic stiffness. Aortic stiffness was assessed by CFPWV, as previously described.22 173 
Briefly, CFPWV was determined by applanation tonometry with simultaneous electrocardiogram 174 
gating of the R-wave to measure the time delay between the foot of the carotid and femoral 175 
arterial pressure waves; PWV was calculated as the distance between arterial sites (m) divided 176 
by the arterial pressure wave transit time (s) at each site, with automated software (Non-177 
Invasive Hemodynamics Workstation, Cardiovascular Engineering Inc.).  178 
Data analysis. Statistical analyses were performed with G*Power 3.1 and GraphPad 179 
Prism version 7. Sample size was estimated based on an effect size to detect significant group 180 
differences in our primary outcome variable (FMD: 0.7) calculated from our laboratory’s previous 181 
intervention studies.23-26 Our sample size estimate indicated that n=18 participants would be 182 
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adequate to detect a difference with >80% power at the =0.05 level; to account for a potentially 183 
lower effect size and subject attrition, we enrolled 24 participants in the study. The impact of 184 
MitoQ on outcome variables was evaluated with paired t-tests. Given the crossover design, we 185 
also tested for the presence of a carryover effect for each of the outcomes using a mixed model 186 
ANOVA, with treatment order as a between group factor (no carryover effects were observed 187 
between conditions). The acute effect of supra-therapeutic MitoQ administration on FMD 188 
following chronic MitoQ and placebo supplementation was assessed with a 2-way repeated 189 
measures ANOVA and Least Significant Differences post-hoc analysis if a significant interaction 190 
was found. Data are expressed as mean ± standard error (SEM). Statistical significance was set 191 
a priori at α=0.05. 192 
 193 
Results 194 
Participants. Fifty-five individuals were consented for the study. Twenty-six did not meet 195 
inclusion criteria. Five individuals withdrew from the study prior to randomization due to the time 196 
commitment (n=4) or study restrictions (n=1). Of the remaining 24 participants, 13 participants 197 
were randomized to Group A, which received MitoQ first followed by placebo, and 11 subjects 198 
were randomized to Group B, which received placebo first followed by MitoQ. Three participants 199 
withdrew from Group A (procedure invasiveness, non-study related injury, and personal 200 
emergency). One participant was excluded from Group B because of an abnormal ECG (atrial 201 
fibrillation). The participant characteristics and clinical blood markers of the 20 participants who 202 
completed the trial are shown in Table 1. Anthropometrics, brachial artery blood pressure, 203 
fasting blood lipids, glucose and physical activity levels were unchanged with the intervention 204 
(Table 1). 205 
Safety and tolerability. Adherence to the intervention was excellent, with all 206 
participants consuming greater than 90% of all MitoQ and placebo capsules administered. The 207 
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20 mg/day dose of MitoQ was well tolerated, and no treatment-related serious adverse events 208 
occurred. A total of 7 treatment-emergent adverse events were reported by 7 of the 24 209 
participants who were enrolled in the study. All self-reported adverse events were mild in 210 
severity and included gastrointestinal discomfort (n=1) during the MitoQ condition and 211 
gastrointestinal discomfort (n=2) and diarrhea (n=1) under the placebo condition; diarrhea (n=2) 212 
and vomiting (n=1) were reported following acute administration of 160 mg of MitoQ. None of 213 
the enrolled participants dropped out of the study because of side effects.  214 
Plasma MitoQ. Plasma levels of MitoQ were higher after 6 weeks of MitoQ 215 
supplementation vs. placebo (Figure 1). The observed levels of MitoQ in plasma are consistent 216 
with the known pharmacokinetic profile of orally ingested MitoQ.10, 11 Moreover, the reported 217 
plasma MitoQ levels likely represent the lowest values achieved during the MitoQ 218 
supplementation phase because they were assessed 24-26 hours after the most recent dose 219 
(~1 hour prior to the subsequent dose).  220 
Vascular endothelial function. BAFMD was 42% higher following chronic MitoQ 221 
supplementation vs. placebo (17/20 subjects had higher values after MitoQ vs. placebo, Figure 222 
2). A post-hoc power analysis revealed an effect size of 0.66 and a statistical power of 80% for 223 
the observed difference in BAFMD (primary outcome). Other brachial artery parameters were 224 
not different between conditions (Supplementary Table 1). Smooth muscle sensitivity to NO 225 
(endothelium-independent dilation), assessed by brachial artery dilation with sublingual 226 
nitroglycerin, was not different between conditions (24±2% vs. 25±3%, for placebo and MitoQ, 227 
respectively, P>0.1). 228 
MtROS-mediated suppression of vascular endothelial function. Oral administration 229 
of a single 160 mg dose of MitoQ increased BAFMD acutely (compared with the pre-230 
administration baseline level) after the placebo supplementation phase, but not after the MitoQ 231 
supplementation phase (n=9; Figure 3). These results are consistent with the idea of reduced 232 
mtROS-mediated suppression of EDD following 6 weeks of chronic MitoQ supplementation.  233 
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Aortic stiffness. There were no differences between conditions in CFPWV in the group 234 
as a whole (placebo: 8.34±0.46 m/s vs. MitoQ: 8.28±0.41 m/s, P>0.1). However, the overall 235 
group consisted of a range of individual subject values in the untreated (placebo arm) condition, 236 
and our previous preclinical study12 found that MitoQ only reduced CFPWV in old mice (i.e., the 237 
group with elevated baseline aortic PWV); there was no effect in young animals. Accordingly, to 238 
determine if MitoQ treatment reduced CFPWV in subjects with elevated levels of CFPWV in the 239 
untreated state, we separated our subjects into 2 subgroups based on the recent Framingham 240 
Heart Study reported cutoff for “healthy vascular aging” of <7.60 m/s, which is the mean +2 241 
standard deviations value from a reference sample of individuals <30 years old without CVD risk 242 
factors.27 The subgroup of our subjects with elevated aortic stiffness in the untreated state 243 
(n=11) was slightly older (69±1 vs. 65±1 years, P<0.05), and had higher systolic blood pressure 244 
(118±2 vs. 105±2 mmHg, P<0.05) and CFPWV (9.74±0.44 vs. 6.52±0.16 m/s, P<0.05) values, 245 
but the cohorts were otherwise not different. CFPWV was lower following MitoQ 246 
supplementation in the cohort with CFPWV values >7.60 m/s (9.25±0.39 m/s; P<0.05), but was 247 
unaltered in the cohort with CFPWV values <7.60 m/s (6.71±0.33 m/s; P>0.1) (Figure 4). MitoQ 248 
did not differentially affect blood pressure in the 2 subgroups. 249 
Circulating markers of oxidative stress and inflammation. Plasma concentrations of 250 
oxidized LDL, a circulating marker of oxidative stress, were 13% lower following 6 weeks of 251 
MitoQ supplementation (Figure 5). There were no differences in circulating markers of 252 
inflammation, as assessed by C-reactive protein (placebo: 1.7±0.4 mg/L vs. MitoQ: 1.5±0.3 253 
mg/L, P>0.1) and IL-6 (placebo:1.3±0.1 mg/L vs. MitoQ: 1.4±0.2 mg/L, P>0.1).  254 
 255 
Discussion 256 
 In the current study, we translated our recent preclinical findings to humans using a 257 
rigorous randomized, placebo-controlled, double-blind crossover study design to evaluate the 258 
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effects of the mitochondrial-targeted antioxidant MitoQ on vascular function in healthy late MA/O 259 
adults. We show that chronic administration of MitoQ increased plasma MitoQ levels and was 260 
safe and well-tolerated over the treatment duration (6 weeks) studied here. Most importantly, we 261 
found that supplementation with MitoQ improved our primary outcome, BAFMD (endothelial 262 
function), in this group with normal (modest) age-related impairments in baseline FMD, and 263 
present evidence that this improvement was mediated, at least in part, by a suppression of 264 
mtROS. MitoQ treatment also reduced aortic stiffness in participants exhibiting age-related 265 
aortic stiffening in the untreated state, and decreased plasma oxidized LDL, a marker of 266 
oxidative stress, without altering circulating markers of inflammation or traditional CVD risk 267 
factors. Collectively, these findings provide support for the concept that MitoQ, and perhaps 268 
other strategies targeting mtROS, may be novel therapeutic options for improving vascular 269 
function and reducing the risk of age-related CVD. 270 
 Preclinical findings from our laboratory show that oral MitoQ supplementation restores 271 
age-related decreases in EDD in old mice.6 To our knowledge, no prior studies have evaluated 272 
supplementation with MitoQ, or any other mitochondria-specific antioxidant, for improving 273 
vascular endothelial function in humans. In the present investigation, we extend our previous 274 
findings on aging in mice to healthy MA/O adults, and demonstrate for the first time that 6 weeks 275 
of MitoQ supplementation improves BAFMD, a measure of NO-mediated EDD and independent 276 
predictor of incident CVD risk.28, 29 The improvement in BAFMD with MitoQ occurred without a 277 
change in endothelium-independent dilation, indicating unaltered vascular smooth muscle 278 
sensitivity to NO and, therefore, that the increase in FMD with treatment reflects an 279 
improvement in endothelium-specific NO-mediated dilation. BAFMD was improved by 42% with 280 
MitoQ in the overall group, and increases were observed in both men and women. This 281 
magnitude of improvement in BAFMD is within the range produced by healthy lifestyle 282 
interventions known for exerting a strong physiological stimulus, such as caloric restriction-283 
based weight loss (~30% improvement)23 and aerobic exercise (~50% improvement in men),30 284 
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when applied for longer durations (up to 3 months) than the present 6-week treatment period. 285 
Given that most MA/O adults do not meet current guidelines for healthy lifestyle behaviors,31-33 286 
MitoQ supplementation may represent an alternative or complementary pharmacological 287 
strategy for enhancing vascular endothelial function in this group. 288 
We found previously that acute ex vivo incubation with MitoQ increased EDD of isolated 289 
arterial segments from old mice,6 and others have reported similar results in skeletal muscle 290 
feed arteries biopsied from older adult humans,7 both of which indicate that age-related 291 
impairments in EDD are mediated by excess mtROS. Furthermore, in our preclinical study, 292 
chronic MitoQ supplementation ameliorated excess mtROS-mediated suppression of EDD in old 293 
mice, as shown by no change in EDD with acute ex vivo incubation of isolated arterial segments 294 
with MitoQ after 4 weeks of oral treatment with MitoQ.6 In the current study, we extend these 295 
findings to an in vivo setting in humans, as we observed an improvement in EDD in response to 296 
an acute supra-therapeutic dose of MitoQ following the placebo phase, which revealed the 297 
presence of tonic inhibition of EDD (BAFMD) by mtROS. The inhibition of EDD by mtROS was 298 
abolished following chronic MitoQ supplementation, as indicated by a lack of further increase in 299 
EDD with acute supra-therapeutic administration of MitoQ. These observations in older humans 300 
support our previous observations in old mice that MitoQ improves vascular endothelial function, 301 
at least in part, by reducing mitochondria-derived oxidative stress. 302 
Our preclinical findings show that MitoQ treatment reduced aortic stiffness, as assessed 303 
by aortic PWV, in old mice.12 MitoQ did not alter aortic stiffness in young mice, suggesting 304 
favorable effects of MitoQ only in a setting of age-related aortic stiffening.12 The current study 305 
translates these findings to humans by showing that MitoQ lowers CFPWV in late MA/O adults 306 
exhibiting age-related aortic stiffening based on recently published cutoffs for CFPWV from the 307 
Framingham Heart Study.27 This finding has potentially important clinical implications in that 308 
CFPWV is the gold-standard in vivo measure of aortic stiffness and an independent predictor of 309 
CVD risk and other common disorders of aging, including cognitive impairment, chronic kidney 310 
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disease and frailty.22, 34-37 MitoQ did not alter aortic stiffness in participants with CFPWV <7.60 311 
m/s, consistent with our previous results in young mice.12  312 
The mechanisms responsible for the de-stiffening effects of MitoQ in our subjects with 313 
elevated CFPWV are not obvious. Endothelial function affects arterial stiffness by influencing 314 
vascular smooth muscle tone22, 38 and average improvements in BAFMD tended to be greater 315 
(51% vs. 36% increase) in the subgroup with elevated initial CFPWV levels, which may have 316 
contributed to their reductions in CFPWV. Our recent findings in mice indicate that MitoQ 317 
treatment improved aortic stiffness in old animals by influencing the elastin component of 318 
intrinsic wall stiffness.12 However, the 6-week supplementation period in the present study in 319 
humans seems too brief to induce changes in structural proteins in the aortic wall and, instead, 320 
suggests functional influences on smooth muscle tone, perhaps linked to reductions in oxidative 321 
stress, as we have reported previously in postmenopausal estrogen-deficient women.39 322 
Importantly, blood pressure was unaltered in the subgroup demonstrating reductions in CFPWV 323 
with MitoQ treatment, indicating that this was not a mechanism. Overall, although future studies 324 
are needed to elucidate responsible mechanisms, our findings provide the first evidence for 325 
chronic MitoQ supplementation lowering aortic stiffness in late MA/O adults with age-related 326 
aortic stiffening. These data have important implications for reducing the risk of CVD and 327 
numerous other age-related disorders linked with elevated aortic stiffness.  328 
In our preclinical studies in mice, MitoQ supplementation normalized age-related 329 
increases in oxidative stress without affecting pro-inflammatory cytokine levels in old animals.6, 330 
12 Consistent with this notion, in the present study MitoQ supplementation was associated with a 331 
decrease in plasma oxidized LDL, a circulating marker of oxidative stress, as well as with 332 
amelioration of mtROS-mediated suppression of EDD. MitoQ supplementation did not alter 333 
circulating markers of inflammation in the current study; moreover, BMI, blood lipids, glucose 334 
and blood pressure were unchanged with MitoQ. These data are in agreement with the lack of 335 
change in these potential modulatory factors observed in our preclinical studies6, 12 and suggest 336 
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that improvements in vascular function observed with MitoQ were independent of overt changes 337 
in traditional CVD risk factors and inflammation. Taken together, these observations support a 338 
reduction in oxidative stress as an important mechanism underlying improvements in vascular 339 
function with MitoQ.  340 
A limitation of the current study is that we did not directly assess the effect of MitoQ on 341 
ROS production by mitochondria. However, the ability of MitoQ to both chronically and acutely 342 
reduce mtROS in the vasculature is supported by: 1) our preclinical study showing that chronic 343 
MitoQ supplementation in old mice reduced aortic mitochondrial superoxide,6 assessed with a 344 
mitochondria-specific spin probe and electron paramagnetic resonance (EPR) spectroscopy - 345 
the gold-standard and most direct measure of ROS;40 and 2) ex vivo experiments in biopsied 346 
skeletal muscle feed arteries from humans demonstrating that 1 hour of MitoQ incubation 347 
improved EDD, which was associated with reduced EPR spectroscopy-based measures of 348 
mitochondrial superoxide levels.7 Regarding the latter assessments of mtROS in human tissue, 349 
we could not perform these invasive analyses in the current clinical intervention study; however, 350 
our innovative acute MitoQ administration paradigm is a direct translation of this experimental 351 
model to humans in vivo and provides evidence for reduced mtROS as a likely mechanism of 352 
action of chronic MitoQ supplementation.  353 
 354 
Perspectives 355 
 Here, we demonstrate for the first time that supplementation with the mitochondria-356 
targeted antioxidant MitoQ is safe and well tolerated in late MA/O adults, improves vascular 357 
endothelial function (likely by suppressing excess mtROS), reduces aortic stiffness in MA/O 358 
adults with elevated initial levels, and decreases oxidized LDL, a circulating marker of oxidative 359 
stress. Collectively, these findings establish the experimental basis for conducting a larger scale 360 
clinical trial in older adults or clinical populations, particularly those associated with endothelial 361 
dysfunction and/or elevated aortic stiffness. In the broadest terms, our results provide initial 362 
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support for the idea that MitoQ and, potentially other mitochondria-targeted antioxidants, may be 363 
an effective treatment for improving vascular function and possibly decreasing the risk of CVD 364 
and other clinical disorders of aging, including cognitive dysfunction and chronic kidney disease.  365 
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Novelty and Significance  513 
 514 
What Is New? 515 
 This is the first trial in humans to show that 6 weeks of daily oral supplementation with 516 
the mitochondrial-targeted antioxidant MitoQ improves vascular endothelial function. 517 
 We provide the first in vivo evidence in humans that MitoQ improves endothelial function 518 
by suppressing mitochondrial-derived oxidative stress. 519 
 We provide the initial evidence in humans that MitoQ supplementation reduces aortic 520 
stiffness in adults with elevated baseline levels. 521 
 522 
What Is Relevant? 523 
 Older individuals have a greater risk for cardiovascular diseases largely because of 524 
vascular dysfunction, including reduced endothelial function and aortic stiffening. Thus, it 525 
is important to establish evidence-based therapeutic options to improve vascular 526 
function in this group.  527 
 This study demonstrates that mitochondrial-targeted antioxidant MitoQ improves 528 
endothelial function and aortic stiffness in healthy late middle-aged and older adults with 529 
impaired baseline vascular function, thus establishing initial evidence for efficacy. 530 
 531 
Summary 532 
 MitoQ supplementation improved vascular endothelial function in healthy late middle-533 
aged and older adults by reducing the tonic suppressive effects of excessive 534 
mitochondrial-specific reactive oxygen species. MitoQ also reduced aortic stiffness in 535 




Figure Legends 539 
 540 
Figure 1. Plasma levels of MitoQ after 6 weeks of placebo or MitoQ supplementation, 541 
assessed ~24 hours after the last dose. Values are presented as mean±SEM. *P<0.05 vs. 542 
placebo. 543 
 544 
Figure 2. Brachial artery flow-mediated dilation (BAFMD) expressed as percent (left) and 545 
absolute (right) change after 6 weeks of placebo or MitoQ supplementation. Values are 546 
presented as mean±SEM, with individual responses below. *P<0.05 vs. placebo.  547 
 548 
Figure 3. Brachial artery flow-mediated dilation (BAFMD) before (-) and 1 hour after (+) acute 549 
ingestion of 160 mg of MitoQ following 6 weeks of placebo or MitoQ supplementation assessed 550 
in a subset of n=9 participants. Values are presented as mean±SEM. ‡P<0.05 vs. before 551 
ingestion of 160 mg MitoQ; *P<0.05 vs. placebo. 552 
 553 
Figure 4. Carotid-femoral pulse wave velocity (CFPWV) after 6 weeks of placebo or MitoQ 554 
supplementation. Participants were separated into 2 subgroups, based on placebo (untreated) 555 
CFPWV values above and below 7.60 m/s (demarcated by the dashed line). Values are 556 
presented as mean±SEM and individual responses are depicted. *P<0.05 vs. placebo. 557 
 558 
Figure 5. Plasma levels of oxidized low-density lipoprotein (LDL), a circulating marker of 559 
oxidative stress, after 6 weeks of placebo or MitoQ supplementation. Values are presented as 560 




Table 1. Participant Characteristics 564 
Characteristics Placebo MitoQ 
N, men/women 9/11 -- 
Age, years 68±1 -- 
Body mass index, kg/m2 23±1 23±1 
Systolic blood pressure, mmHg 113±3 114±4 
Diastolic blood pressure, mmHg 67±1 67±1 
Resting heart rate, beats/min 62±2 61±1 
Physical activity caloric expenditure, kcal/wk 5201±570 5326±726 
Total cholesterol, mmol/L 4.9±0.2 4.9±0.2 
High-density lipoprotein cholesterol, mmol/L 1.3±0.1 1.3±0.1 
Low-density lipoprotein cholesterol, mmol/L 3.1±0.2 3.0±0.2 
Triglycerides, mmol/L 1.2±0.2 1.2±0.1 
Glucose, mmol/L 4.7±0.1 4.6±0.1 
Data are mean±SEM 565 
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